Trial Profile
The effect of liraglutide on pancreatic hormones and its size.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- Acronyms LIRAP
- 25 Sep 2020 Primary endpoint (Volumetric Changes of the Pancreas) has not been met as per results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes.
- 25 Sep 2020 Results assessing Effects of a six-week intervention with glucagon like peptide 1 receptor analogue on pancreatic volume, oedema and DNA synthesis in obese men, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 23 Mar 2020 Status changed from active, no longer recruiting to completed.